Kaleido Competitors

Pink Sheets . USA . 
Stock . Kaleido Biosciences
KLDO Stock  USD 0.0001  0.00  0.00%   
Kaleido Biosciences competes with Gilead Sciences, Sanofi ADR, Amgen, GlaxoSmithKline PLC, and Bristol Myers; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Kaleido Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Kaleido Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Kaleido Biosciences Correlation with its peers.

Kaleido Biosciences vs Novo Nordisk Correlation

Good diversification

The correlation between Kaleido Biosciences and NVO is -0.07 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Kaleido Biosciences and NVO in the same portfolio, assuming nothing else is changed.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kaleido Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.000150.01
Details
Intrinsic
Valuation
LowRealHigh
0.000.00009650.01
Details
Naive
Forecast
LowNextHigh
0.0000020.0001220.22
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.00010.00010.0001
Details

Kaleido Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Kaleido Biosciences and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Kaleido and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Kaleido Biosciences does not affect the price movement of the other competitor.

High positive correlations

BSX
+ 0.89
SNY
BMY
+ 0.89
GSK
AMGN
+ 0.65
GILD
GSK
+ 0.63
AMGN
NVO
+ 0.63
BMY
BSX
+ 0.57
SYK
  

High negative correlations

BMY
- 0.79
SNY
BSX
- 0.69
BMY
GSK
- 0.65
SNY
NVO
- 0.64
SNY
NVO
- 0.52
BSX
BSX
- 0.51
GSK

Risk-Adjusted Indicators

There is a big difference between Kaleido Pink Sheet performing well and Kaleido Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kaleido Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Kaleido Biosciences Competitive Analysis

The better you understand Kaleido Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Kaleido Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Kaleido Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
KLDO GILD SNY AMGN GSK BMY SYK BSX NVO
 0.00 
 0.0001 
Kaleido
 1.69 
 139.55 
Gilead
 1.82 
 47.04 
Sanofi
 0.31 
 342.94 
Amgen
 1.82 
 50.66 
GlaxoSmithKline
 1.40 
 54.28 
Bristol
 4.13 
 354.30 
Stryker
 1.28 
 92.33 
Boston
 0.17 
 59.33 
Novo
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Good
Good
Weakest
Good
Good
Good
Soft
Weakest
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Low
Low
Low
Low
Small
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Buy
Hold
Buy
Strong Buy
Strong Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Hold
Strong Hold
Cautious Hold
Buy
Strong Buy
Cautious Hold
Strong Hold
Strong Sell
Current Ratio
1.42
1.43
1.3
1.68
1.43
1.42
2.0
1.45
0.92
Net Asset
50.14 M
58.99 B
126.81 B
91.84 B
59.46 B
92.6 B
47.84 B
39.4 B
465.8 B
Profit Margin
N/A
0.28
0.17
0.19
0.17
0.13
0.12
0.14
0.33
EBITDA
(85.09 M)
4.43 B
12.68 B
13.36 B
6.67 B
3.17 B
5.69 B
3.94 B
137.38 B
Operating Margin
-79.28
0.45
0.12
0.34
0.33
0.32
0.22
0.21
0.44
Current Valuation
(16.73 M)
190.73 B
126.66 B
229.81 B
123.25 B
145.04 B
152.09 B
147.7 B
275 B
Price To Book
0.0044
8.04
1.3
21.55
4.58
5.96
6.3
5.85
9.64
Retained Earnings
(197.63 M)
11.5 B
67.5 B
(27.59 B)
7.8 B
14.91 B
18.53 B
2.67 B
144.45 B
Current Asset
72.93 M
1.18 B
24.93 B
38.52 B
16.59 B
10.41 B
1.15 B
1.21 B
8.03 B
Five Year Return
N/A
3.76
3.85
2.82
5.32
2.96
1.07
N/A
2.05
Beta
0.42
0.35
0.4
0.45
0.25
0.3
0.9
0.67
0.36
Number Of Employees
76
17.6 K
82.88 K
28 K
68.63 K
34.1 K
53 K
53 K
78.55 K
Shares Outstanding
42.62 M
1.24 B
2.42 B
538.48 M
2.02 B
2.04 B
382.42 M
1.48 B
3.37 B
Cash Flow From Operations
(77.09 M)
10.83 B
10.75 B
11.49 B
6.55 B
15.19 B
5.04 B
3.44 B
120.97 B
Annual Yield
N/A
0.0226
0.0475
0.0282
0.0337
0.0464
0.0099
N/A
0.0291
Total Debt
5.55 M
26.71 B
20.33 B
60.1 B
16.99 B
51.2 B
14.86 B
11.15 B
102.79 B
Return On Equity
-5.81
0.41
0.0666
0.82
0.42
0.34
0.14
0.12
0.71
Z Score
-6.3
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-1.0
0.13
0.045
0.0771
0.0713
0.0939
0.075
0.0576
0.21
Number Of Shares Shorted
2.34 M
22.97 M
8.5 M
13.96 M
17.55 M
36.98 M
4.68 M
23.42 M
28.16 M
Book Value Per Share
0.25
17.34
70.49
17.86
5.54
9.11
56.97
15.78
6.13
Current Liabilities
10.39 M
104.89 M
16.82 B
8.67 B
13.42 B
8.02 B
707.5 M
923 M
5.95 B
Total Asset
50.14 M
58.99 B
126.81 B
91.84 B
59.46 B
92.6 B
47.84 B
39.4 B
465.8 B
Debt To Equity
2.05
1.3
0.3
N/A
0.98
1.32
0.88
0.51
0.34
Short Ratio
29.34
3.62
2.98
5.1
4.97
2.48
2.66
2.48
1.45
Target Price
22.0
139.46
58.2
332.7
52.35
58.04
426.15
124.41
59.17
Last Dividend Paid
N/A
3.14
4.12
9.39
0.64
2.48
N/A
N/A
11.65
Shares Owned By Institutions
0.36
92.17
9.97
84.26
19.22
82.01
82.12
95.06
9.14
Market Capitalization
421.96 K
176.13 B
114.16 B
184.1 B
103.46 B
112.07 B
141.33 B
138.71 B
260.85 B
Price To Earning
-1.45
359.42
7.78
22.74
11.8
24.88
63.07
107.05
37.42
Price To Earnings To Growth
N/A
0.25
0.68
0.96
0.42
2.26
1.52
0.9
2.84
Price To Sales
0.0425
6.06
2.44
5.12
3.22
2.33
5.8
7.17
0.83
Net Income
(90.29 M)
480 M
7.81 B
4.09 B
2.95 B
(8.93 B)
3.25 B
1.85 B
100.99 B
Earnings Per Share
-2.16
6.57
2.43
12.89
3.68
2.97
8.39
1.9
3.76
Shares Owned By Insiders
0.73
0.09
N/A
0.21
0.06
0.08
5.3
0.19
N/A
Revenue
1.1 M
28.75 B
46.72 B
33.42 B
31.38 B
48.3 B
25.12 B
16.75 B
290.4 B
Working Capital
62.54 M
7.17 B
13.43 B
5.93 B
(4.7 B)
6.01 B
7.23 B
521 M
(56.63 B)
Cash And Equivalents
38.47 M
6.14 B
6.9 B
11.48 B
2.75 B
10.35 B
3.65 B
414 M
37.47 B
Cash Per Share
0.9
4.9
2.76
21.51
0.32
6.21
2.98
0.24
16.57
Gross Profit
(66.7 M)
22.9 B
33.67 B
25.2 B
23.3 B
35.14 B
15.86 B
13.22 B
263.33 B
Day Typical Price
1.0E-4
139.43
46.95
342.99
50.79
54.55
354.86
92.37
59.35
Accumulation Distribution
N/A
0.0162
0.014
0.0245
0.009
0.0174
0.0268
0.02
0.0189
Market Facilitation Index
N/A
2.28
0.66
8.52
0.46
0.96
9.63
1.87
1.13
Daily Balance Of Power
0.0
(1.05)
1.272727
0.1244
(2.04)
(0.80)
(1.58)
(0.64)
(0.09)
Period Momentum Indicator
N/A
(2.40)
0.84
1.06
(0.94)
(0.77)
(15.26)
(1.20)
(0.10)
Rate Of Daily Change
1.0
0.98
1.02
1.0
0.98
0.99
0.96
0.99
1.0
Day Median Price
1.0E-4
139.37
46.91
343.01
50.86
54.69
355.14
92.39
59.36
Price Action Indicator
N/A
(1.02)
0.55
0.46
(0.67)
(0.79)
(8.46)
(0.66)
(0.09)
Relative Strength Index
50.03
63.8
46.96
59.13
56.53
55.86
47.78
44.94
57.22
Coefficient Of Variation
846.86
694.64
(1,008)
663.82
533.48
518.21
(1,291)
(1,115)
1345.25
Mean Deviation
146.32
1.33
1.02
1.22
1.08
1.32
0.938
1.07
2.15
Jensen Alpha
70.39
0.2427
(0.16)
0.2719
0.2456
0.3371
(0.11)
(0.16)
0.2184
Total Risk Alpha
42.11
0.15
(0.20)
0.1746
0.1852
0.2592
(0.17)
(0.21)
0.064
Sortino Ratio
N/A
0.129
N/A
0.1463
0.1806
0.2333
N/A
N/A
0.076
Downside Variance
N/A
2.31
N/A
2.4
1.46
1.81
N/A
N/A
4.79
Standard Deviation
603.75
1.67
1.27
1.8
1.4
1.86
1.3
1.42
2.84
Kurtosis
65.89
(0.22)
(0.16)
4.09
1.45
2.55
3.28
0.8723
1.07
Potential Upside
N/A
3.01
1.87
3.47
2.38
3.59
1.65
1.73
5.8
Treynor Ratio
2.8
(0.68)
(0.24)
(0.90)
1.21
1.02
(1.32)
(0.26)
(0.41)
Maximum Drawdown
4998.0
6.7
5.92
11.18
8.39
11.16
6.72
7.34
13.19
Variance
364515.25
2.8
1.63
3.25
1.97
3.46
1.7
2.02
8.08
Market Risk Adjusted Performance
2.81
(0.67)
(0.23)
(0.89)
1.22
1.03
(1.31)
(0.25)
(0.40)
Risk Adjusted Performance
0.0954
0.1098
(0.07)
0.1149
0.1404
0.1457
(0.05)
(0.06)
0.0612
Skewness
8.11
0.0646
(0.30)
1.16
0.4635
1.04
0.5272
(0.15)
0.9469
Semi Deviation
N/A
1.34
N/A
1.17
0.9313
1.04
N/A
N/A
2.02
Information Ratio
0.118
0.1171
(0.13)
0.1257
0.1554
0.1688
(0.11)
(0.12)
0.0585
Value At Risk
N/A
(2.41)
(2.19)
(2.59)
(1.83)
(1.98)
(2.03)
(2.23)
(3.04)
Expected Short fall
N/A
(1.52)
N/A
(1.30)
(1.26)
(1.65)
N/A
N/A
(2.55)
Downside Deviation
N/A
1.52
N/A
1.55
1.21
1.35
N/A
N/A
2.19
Semi Variance
N/A
1.79
N/A
1.37
0.8673
1.09
N/A
N/A
4.07

Kaleido Biosciences Competition Performance Charts

Five steps to successful analysis of Kaleido Biosciences Competition

Kaleido Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Kaleido Biosciences in relation to its competition. Kaleido Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Kaleido Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Kaleido Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Kaleido Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Kaleido Biosciences position

In addition to having Kaleido Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Online Gaming Thematic Idea Now

Online Gaming
Online Gaming Theme
Companies that are involved in the building and marketing of online gaming-related products. The Online Gaming theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Online Gaming Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Kaleido Pink Sheet

Kaleido Biosciences financial ratios help investors to determine whether Kaleido Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kaleido with respect to the benefits of owning Kaleido Biosciences security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY